References
- 1. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013; 122(23): 3723-34.
- 2. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, et al. Chronic lympho-cytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Hae-matol. 2007; 139(5): 809-19.
- 3. Speedy HE, Sava G, Houlston RS. Inherited suscepti-bility to CLL. Adv Exp Med Biol. 2013; 792: 293-308.
- 4. Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6): 575-83.
- 5. Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymp-hocytosis: right track or red herring? Blood. 2012; 119(19): 4358-62.
- 6. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(24): 3959-63.
- 7. Gribben JG, Riches JC. Immunotherapeutic strategies including transplantation: eradication of disease. He-matology Am Soc Hematol Educ Program. 2013; 2013: 151-7.
- 8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. International Work-shop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lympho-cytic leukemia: a report from the International Work-shop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12): 5446-56.
- 9. Damle RN, Calissano C, Chiorazzi N. Chronic lymp-hocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 2010; 23(1): 33-45.
- 10. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910-6.
- 11. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferra-cin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39): 13944-9.
- 12. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lym-phocytic leukemia. Cancer Cell. 2010; 17(1): 28-40.
- 13. Lia M, Carette A, Tang H, Shen Q, Mo T, Bhagat G, et al. Function-al dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood. 2012; 119(13): 2981-90.
- 14. Rossi D, Fangazio M, Gaidano G. The spectrum of genetic defects in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2012; 4(1): e2012076.
- 15. Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lympho-cytic leukemia patients with favorable outcome. Blood. 2014; 123(24): 3790-6.
- 16. Burger JA, Gribben JG. The microenvironment in chr-onic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014; 24: 71-81.
- 17. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001; 97(9): 2777-83.
- 18. Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007; 109(4): 1660-8.
- 19. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bom-ben R, Marasca R, et al. Intrinsic and extrinsic fac-tors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med. 2009; 7: 76.
- 20. Petlickovski A, Laurenti L, Li X, Marietti S, Chiu-solo P, Sica S, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005; 105(12): 4820-7.
- 21. Efremov DG, Gobessi S, Longo PG. Signaling path-ways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev. 2007; 7(2): 102-8.
- 22. Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, et al. Surface IgM stimulation indu-ces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012; 119(1): 170-9.
- 23. Kostareli E, Gounari M, Agathangelidis A, Stamato-poulos K. Immunoglobulin gene repertoire in chronic lymphocytic leukemia: insight into antigen selection and microenvironmental interactions. Mediterr J Hematol Infect Dis. 2012; 4(1): e2012052.
- 24. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoim-mune diseases. Blood. 1993; 81(10): 2475-87.
- 25. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibo-dy repertoire. Immunol Today. 1994; 15(6): 288-94.
- 26. Efremov DG, Ivanovski M, Siljanovski N, Pozzato G, Cevreska L, Fais F, et al. Restricted immuno-globulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic ane-mia. Blood. 1996; 87(9): 3869-76.
- 27. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004; 200(4): 519-25.
- 28. Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K, et al. Subsets with restricted immu-noglobulin gene rearrangement features indicate a role for antigen selection in the development of chro-nic lymphocytic leukemia. Blood. 2004; 104(9): 2879-85.
- 29. Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leuke-mia B cells of more than 1% of patients express vir-tually identical immunoglobulins. Blood. 2004; 104(8): 2499-504. 30. Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012; 119(19): 4467-75. 31. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998; 102(8): 1515-25. 32. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6): 1840-7. 33. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Ste-venson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6): 1848-54. 34. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194(11): 1639-47. 35. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microen-vironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117(2): 563-74. 36. Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL, et al. The actin and tetraspanin net-works organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity. 2013; 38(3): 461-74.
- 37. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a promistream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008; 111(2): 846-55.
- 38. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, Efremov DG. Overexpression of the autoimmunity-associated phosphatase PTPN22 pro-motes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood. 2012; 119(26): 6278.87.
- 39. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005; 115(2): 369.78.
- 40. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor sig-naling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lym-phoma B cells. Blood. 2007; 109(5): 2032.9.
- 41. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. 2009; 23(4): 686.97.
- 42. Ringshausen I, Schneller F, Bogner C, Hipp S, Duy-ster J, Peschel C, Decker T. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002; 100(10): 3741.8.
- 43. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-Ɣ inhibitor CAL-101 shows promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12): 2078.88.
- 44. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treat-ment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23): 6287.96.
- 45. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-indepen-dent cell-autonomous signalling. Nature. 2012; 489(7415): 309.12.
- 46. Binder M, Muller F, Frick M, Wehr C, Simon F, Leistler B, et al. CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood. 2013; 121(1): 239.41.
- 47. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008; 111(7): 3838.3848.
- 48. Chu CC, Catera R, Hatzi K, et al. Chronic lymp-hocytic leukemia antibodies with a common stereo-typic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood. 2008; 112(13): 5122.9.
- 49. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epi-topes associated with apoptosis and oxidation. Mol Med. 2008; 14(11.12): 665.74.
- 50. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of ori-gin. Blood. 2010; 115(19): 3907.15.
- 51. Binder M, Lechenne B, Ummanni R, et al. Stereoty-pical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One. 2010; 5(12): e15992.
- 52. Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013; 210: 59.70.
- 53. Kostareli E, Gounari M, Janus A, et al. Antigen re-ceptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia. 2012; 26: 1127.31.
- 54. Hoogeboom R, Wormhoudt TA, Schipperus MR, et al. A novel chronic lymphocytic leukemia subset ex-pressing mutated IGHV3-7-encoded rheumatoid fac-tor B-cell receptors that are functionally proficient. Leukemia. 2013; 27: 738.40.
- 55. Iacovelli S, Hug E, Bennardo S, Duehren-von Minden M, Gobessi S, Rinaldi A, et al. Two types of BCR interactions are positively selected during leukemia development in the Eµ-TCL1 transgenic mouse model of CLL. Blood. 2015 Jan 6. pii: blood-2014-07-587790. [Epub ahead of print] 56. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002; 99(10): 6955.60.
- 57. Chiorazzi N, Efremov DG. Chronic lymphocytic leu-kemia: a tale of one or two signals? Cell Res. 2013; 23(2): 182.5.
- 58. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, et al. Self-renewing hemato-poietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011; 20(2): 246.59.
- 59. Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM, et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep. 2013; 4(3): 566.77.
- 60. Rasi S, Monti S, Spina V, Foa R, Gaidano G, Rossi D. Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. Haematologica. 2012; 97(1): 153.4.
- 61. Greco M, Capello D, Bruscaggin A, Spina V, Rasi S, Monti S, et al. Analysis of SF3B1 mutations in mo-noclonal B-cell lymphocytosis. Hematol Oncol. 2013; 31(1): 54.5.
- 62. Efremov DG, Bomben R, Gobessi S, Gattei V. TLR9 signaling defines distinct prognostic subsets in CLL. Front Biosci (Landmark Ed). 2013; 18: 371.86.
- 63. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lympho-cytic leukemia. N Engl J Med. 2000; 343(24): 1750-7.
- 64. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19(5): 1414-20.
- 65. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. International Group of In-vestigators; German Chronic Lymphocytic Leukae-mia Study Group. Addition of rituximab to fludara-bine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747): 1164-74.
- 66. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112(4): 975-80.
- 67. Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009; 27(4): 498-503.
- 68. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30(26): 3209-16.
- 69. Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effective-ness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. Ther Adv Hematol. 2013; 4(3): 157-71.
- 70. Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Piccirillo N, et al. Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience. Mediterr J Hematol Infect Dis. 2013; 5(1): e2013031.
- 71. Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014; 89(5): 480-6.
- 72. Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlo-rambucil as first-line treatment for chronic lym-phocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014; 32(12): 1236-41.
- 73. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chloram-bucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12): 1101-10.
- 74. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, Efremov DG. The Syk inhibitor fosta-matinib disodium (R788) inhibits tumor growth in the Eµ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood. 2010; 116(23): 4894.905.
- 75. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, et al. Spleen tyrosine kinase is overex-pressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009; 69(13): 5424.32.
- 76. Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, et al. The tyrosine kinase Syk regulates the survival of chronic lympho-cytic leukemia B cells through PKCdelta and pro-teasome-dependent regulation of Mcl-1 expression. Oncogene. 2009; 28(37): 3261.73.
- 77. Efremov DG, Laurenti L. The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs. 2011; 20(5): 623.36.
- 78. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lym-phocytic leukemia. Blood. 2010; 115(13): 2578.85.
- 79. Woyach JA, Johnson AJ, Byrd JC. The B-cell recep-tor signaling pathway as a therapeutic target in CLL. Blood. 2012; 120(6): 1175.84.
- 80. Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014; 57(9): 3856.73.
- 81. Sharman JP, Klein LM, Boxer M, Kolibaba KS, Abella-Dominicis E, Hawkins MJ, Di Paolo J, Hu J, Reddy A, Jin F, Melchor-Khan F, Yasenchak CA. Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL). J Clin Oncol 32: 5s, 2014 (suppl; abstr 7007).
- 82. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling path-way determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007; 21(1): 110.20.
- 83. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13(2): 140.56.
- 84. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110-delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117(2): 591.4.
- 85. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phospho-inositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118(13): 3603-12.
- 86. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110ä, for relap-sed/refractory chronic lymphocytic leukemia. Blood. 2014; 123(22): 3390-7.
- 87. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11): 997-1007.
- 88. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, et al. Bruton's tyrosine kinase (BTK) function is important to the develop-ment and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014; 123(8): 1207-13.
- 89. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013; 31(1): 88-94.
- 90. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32-42.
- 91. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 213-23.
- 92. O'Brien S, Furman RR, Coutre SE, Sharman JP, Bur-ger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leuka-emia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014; 15(1): 48-58.
- 93. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014; 15(10): 1090-9.
- 94. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39): 13944-9.
- 95. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012; 30(5): 488-96.
- 96. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor acti-vity while sparing platelets. Nat Med. 2013; 19(2): 202-8.
- 97. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, et al. Humerickhouse RA, Roberts AW. Bcl-2 Inhibitor ABT-199 (GDC-0199) Monothe-rapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013; 122: 872.
- 98. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014; 65: 333-47.
- 99. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chro-nic lymphoid leukemia. N Engl J Med. 2011; 365(8): 725-33.
- 100. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509-18.
- 101. Kochenderfer JN, Dudley ME, Kassim SH, Somer-ville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-Refractory Diffuse Large B-Cell Lym-phoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expres-sing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol. 2014 Aug 25. pii: JCO.2014.56.2025.
- 102. Porter DL, Kalos M, Frey NV, Grupp SA, Loren AW, Jemison C, et al. Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Du-rable Responses In Relapsed, Refractory CLL. Blood. 2013; 122: 4162.
- 103. Woyach JA, Furman RR, Liu TM, Ozer HG, Za-patka M, Ruppert AS, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014; 370(24): 2286-94.
- 104. Laurenti L, De Padua L, D'Arena G, Vannata B, In-nocenti I, Tarnani M, et al. New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Mini Rev Med Chem. 2011; 11(6): 508-18.
- 105. Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leuke-mia. 2014; 28(5): 1163-7.
- 106. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014; 123(12): 1957-60.
- 107. Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, et al. High-throughput combinatorial scre-ening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lym-phoma cells. Proc Natl Acad Sci U S A. 2014; 111(6): 2349-54.